Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the ...
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...
Hosted on MSN1d
Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 ProjectionsShares of Eli Lilly & Co. dropped over 7% on Tuesday morning, reaching levels last seen in late November and marking the ...
((This Jan. 13 story has been corrected to say 'drugmakers will ask,' not 'Eli Lilly has asked' to pause negotiations, after ...
Key Takeaways Eli Lilly shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year.The ...
The UK has become a “relatively small market” since leaving the European Union and must develop a different investment proposition from its counterparts in order to be interesting to ...
Peer Conversations explores successful leadership through the personal and professional choices of the most influential ...
Eli Lilly (NYSE:LLY) shares sold off on Tuesday after the Indiana-based pharma giant's Q4 and 2024 preliminary sales results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback